DNA X Regains Nasdaq Compliance, Avoids Delisting
SONM sits 45% above its 52-week low of $2.521 on light trading volume (0.4× avg).
Summary
DNA X regained Nasdaq compliance after raising equity above the $2.5 million minimum, but remains under a one-year panel monitor with no cure period if it falls out of compliance again.
Key Events · Legal and Risk Events · SONM
-
Nasdaq Compliance Regained
The Nasdaq Hearings Panel determined on August 28, 2026 that DNA X has regained compliance with Listing Rule 5550(b)(1), requiring stockholders' equity of at least $2.5 million.
-
Mandatory Panel Monitor Until 2027
The company is subject to a mandatory panel monitor until August 28, 2027. If it falls out of compliance again, it will not be permitted to submit a compliance plan or receive a cure period, and Nasdaq will issue a delisting determination letter.
-
Delisting Risk Remains Conditional
Pursuant to the Panel's July 24, 2026 decision, the company's securities remain subject to delisting if it fails to maintain compliance with all Nasdaq Listing Rules until November 18, 2026.
-
Prior Financing Enabled Compliance
The compliance determination follows the completion of the Series B preferred stock sale disclosed on August 13, 2026, which raised $2.5 million and projected stockholders' equity above the Nasdaq minimum.
Analysis · SONM · Manufacturing
Formal confirmation from the Nasdaq Hearings Panel that DNA X has regained compliance with the stockholders' equity requirement removes the immediate delisting threat. The company remains under a mandatory panel monitor until August 28, 2027, meaning any future equity shortfall would trigger an expedited delisting process with no cure period. This is a critical survival milestone for a company that recently disclosed going concern language and a material weakness in internal controls.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30.2% of the 2009 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SONM was trading at $3.66 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $5.4M. The 52-week trading range was $2.52 to $16.97. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.